These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15358376)

  • 1. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of the interaction between MDM2 and p53.
    Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
    J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
    Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
    Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoinhibition of MDMX by intramolecular p53 mimicry.
    Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
    Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
    FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
    Uldrijan S; Pannekoek WJ; Vousden KH
    EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.
    Dumaz N; Meek DW
    EMBO J; 1999 Dec; 18(24):7002-10. PubMed ID: 10601022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
    Kulikov R; Boehme KA; Blattner C
    Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.